PAVmed Announces Reverse Stock Split

Rhea-AI Summary

PAVmed (NASDAQ: PAVM) will implement a 1-for-30 reverse stock split of its common stock effective January 2, 2026 at 12:01 a.m. ET. The split-adjusted shares will begin trading on Nasdaq under the symbol PAVM at market open on January 2, 2026.

The reverse split is intended to bring the company into compliance with Nasdaq's $1.00 minimum bid requirement. The company's authorized common shares will be reduced from 250,000,000 to 25,000,000. Equity awards, outstanding options, convertible securities, and ESPP allocations will be proportionately adjusted; fractional shares will be rounded up to whole shares. New CUSIP: 70387R502.

Positive

• Reverse split ratio: 1-for-30 effective Jan 2, 2026
• Action aims to meet Nasdaq $1.00 minimum bid requirement
• Authorized shares reduced from 250,000,000 to 25,000,000
• Outstanding options and convertibles will be proportionately adjusted
• Fractional shares will be rounded up to nearest whole share

Negative

• Company needed a reverse split to seek compliance with Nasdaq $1.00 minimum bid
• Authorized common shares cut by 90% may limit future share availability
• Equity incentive and ESPP share counts will be proportionately reduced

Key Figures

Reverse split ratio 1-for-30 Common stock reverse split effective January 2, 2026

Effective time 12:01 a.m. Eastern Time Reverse split effective time on January 2, 2026

Authorized shares before 250,000,000 Common Stock authorized prior to reverse split

Authorized shares after 25,000,000 Common Stock authorized after reverse split completion

Stockholder approval date December 5, 2025 Special meeting approving reverse split parameters

Board approval date December 8, 2025 Board selected 1-for-30 ratio

New CUSIP 70387R 502 CUSIP for Common Stock post reverse split

Market Reality Check

$1.07 Last Close

Volume Volume 412,547 is below the 20-day average of 703,472 (relative volume 0.59x). low

Technical Price $1.07 is trading below the $1.19 200-day moving average and 40.56% under the 52-week high.

Peers on Argus 1 Down

Peers in Medical Devices showed mixed moves, with names like ICAD up 3.48% and SERA down 5.49%. Only HYPR appeared on the momentum scanner, down 6.99%, suggesting stock-specific rather than sector-wide drivers.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Sep 16	Executive appointment	Positive	+0.9%	Senior VP hire to expand market access and government affairs capabilities.
Sep 11	Equity offering close	Negative	+4.9%	Closing of common stock offering raising net proceeds of about $26.9M.
Sep 10	Offering pricing	Negative	-19.7%	Public offering priced at $1.00 per share with additional option to underwriters.
Sep 09	Offering announcement	Negative	-19.7%	Proposed underwritten public offering of common stock for working capital.
Sep 05	Investor call notice	Neutral	-0.7%	Announcement of investor call on MolDX meeting for EsoGuard coverage.

Pattern Detected

Equity offerings have generally pressured the stock, with two September offering announcements followed by sharp negative reactions, while the closing of the offering saw a positive divergence. Non-financing news (management changes, calls) has led to modest moves.

Recent Company History

Over the last few months, Lucid Diagnostics has focused on capital raising and corporate development. In early September 2025, a sequence of underwritten equity offerings (proposed, priced, and closed) around $1.00 per share drove large negative reactions on announcement but a positive move on closing. Subsequent filings, including Q3 2025 results with a going concern warning, and governance or personnel updates, frame a company balancing funding needs with commercialization of its EsoGuard test. The current reverse split news for its parent occurs against this backdrop.

Market Pulse Summary

This announcement details a 1-for-30 reverse stock split effective January 2, 2026, aimed at meeting Nasdaq’s minimum bid requirement while also reducing authorized shares from 250,000,000 to 25,000,000. Historical context shows recent equity offerings and a going concern warning at the subsidiary level, underscoring capital-structure and funding risk. Investors may watch post-split trading, future financing activity, and any updates on operational progress for additional context.

Key Terms

reverse stock split financial

"today announced it will conduct a 1-for-30 reverse stock split of its common stock"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Nasdaq Capital Market regulatory

"Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

convertible securities financial

"the Company's outstanding stock options, and the conversion prices of the Company's outstanding convertible securities, including its convertible debt"

Convertible securities are bonds or preferred shares that can be exchanged for a company’s common stock at a predetermined price or under specified conditions. They matter because they combine the steadiness of a loan or fixed dividend with the potential upside of ownership; like a safety‑net that carries a one‑time ticket to become a shareholder, they affect expected returns and can dilute existing stock if converted.

convertible debt financial

"conversion prices of the Company's outstanding convertible securities, including its convertible debt and preferred stock"

A convertible debt is a loan a company takes that gives the lender the option to swap the owed money for a set number of the company’s shares instead of getting cash back. It matters to investors because it can change who owns the company and how much their shares are worth: if lenders convert, existing shareholders can be diluted, but conversion can also signal confidence and reduce a company’s cash pressure — like getting a coupon that can be redeemed for store ownership rather than a refund.

CUSIP regulatory

"The new CUSIP number for the Common Stock following the reverse stock split is 70387R 502"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM" and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining the listing of its Common Stock on Nasdaq.

The reverse stock split was approved by the Company's stockholders at the Company's special meeting of stockholders held on December 5, 2025, with the specific ratio to be determined at the discretion of the Company's board of directors within approved parameters. The ratio of 1-for-30 was approved by the board on December 8, 2025. As of the effective time of the reverse stock split, the authorized shares of Common Stock will be reduced from 250,000,000 to 25,000,000 (which reduction was approved, subject to completion of the reverse stock split, by the Company's stockholders at the same special meeting).

As a result of the reverse stock split, the number of shares of Common Stock available for issuance under the Company's equity incentive plan and employee stock purchase plan immediately prior to the reverse stock split will be proportionately reduced. In addition, the exercise prices of and number of shares subject to the Company's outstanding stock options, and the conversion prices of the Company's outstanding convertible securities, including its convertible debt and preferred stock, will likewise be proportionately adjusted in accordance with their respective terms. 

No fractional shares of Common Stock will be issued in connection with the reverse stock split. Stockholders that would hold a fractional share of Common Stock as a result of the reverse stock split will have such fractional shares of Common Stock rounded up to the nearest whole share of Common Stock.

The new CUSIP number for the Common Stock following the reverse stock split is 70387R 502.

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard^® Esophageal DNA Test and EsoCheck^® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

For more and for more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com. 

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-announces-reverse-stock-split-302650410.html

SOURCE PAVmed Inc.

FAQ

What reverse split did PAVmed (PAVM) announce and when does it take effect?

PAVmed announced a 1-for-30 reverse stock split that becomes effective on January 2, 2026 at 12:01 a.m. ET.

Why is PAVmed (PAVM) doing a 1-for-30 reverse split?

The reverse split is intended to bring the company's common stock into compliance with Nasdaq's $1.00 minimum bid requirement.

Will PAVmed (PAVM) keep the same ticker after the reverse split?

Yes. The company will continue trading on Nasdaq under the symbol PAVM and will trade on a split-adjusted basis starting January 2, 2026.

How does the reverse split affect PAVmed's authorized shares and equity plans?

Authorized common shares will be reduced from 250,000,000 to 25,000,000, and shares available under the equity incentive plan and ESPP will be proportionately reduced.

What happens to fractional PAVmed (PAVM) shares after the reverse split?

No fractional shares will be issued; fractional holdings will be rounded up to the nearest whole share.

Will outstanding options and convertible securities be adjusted for PAVmed's reverse split?

Yes. Exercise prices, number of shares under options, and conversion prices of convertible securities will be proportionately adjusted in accordance with their terms.